Articles Tagged With: zoster
-
Adjuvanted Zoster Vaccine: Persistent Protection
The adjuvanted recombinant zoster vaccine efficacy is high and persistent, with apparent plateauing at > 84% four to six years after vaccination.
-
Herpes Zoster Vaccine — Effective but Underused
The adjuvanted recombinant herpes zoster vaccine is highly effective in practice, but it is vastly underused.
-
About Face: A Review of Facial Paralysis for Emergency Clinicians
Emergency medicine clinicians routinely encounter patients with facial paralysis and need a straightforward way to filter through the wide range of differential diagnoses. This article reviews the fundamentals of facial paralysis, including its epidemiology, anatomy, and differential diagnosis.
-
Infectious Disease Alert Updates
Changing Herpes Zoster Risk in Adults; Trends in Herpes Zoster Risk Among Children
-
Zoster Vaccine Recombinant Adjuvanted (Shingrix)
The FDA has approved a second zoster vaccine for the prevention of shingles in adults.
-
Varicella Zoster Virus and Granulomatous Arteritis
Varicella zoster virus antigen was identified in 11 of 11 aortas with pathologically verified granulomatous arteritis and in only five of 18 control aortas from surgical or autopsy specimens.
-
The Zoster Vaccine Rapidly Loses Effectiveness in Adults Over 60
An observational study from Kaiser Permanente Southern California showed that while the shingles vaccine reduces the risk of herpes zoster, there is a major decline in effectiveness over just eight years in older adults.
-
Risk of Herpes Zoster Increases After Zoster Vaccination in Patients Taking Immunosuppressive Medications
In adults >18 years, taking immunosuppressive medications at the time of zoster vaccination increased the risk for herpes zoster for up to 6 weeks afterward (adjusted odds ratio, 2.99; 95% CI, 1.58-5.70).